Erratum: Three differentiation states risk-stratify bladder cancer into distinct subtypes (Proc Natl Acad Sci USA (2012) 109, 6 (2078-2083) DOI: 10.1073/pnas.1120605109);Three differentiation states risk-stratify bladder cancer into distinct subtypes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 6, 2012, Pages 2078-2083

  Volkmer, Jens Peter ^a,b,d   Sahoo, Debashis ^a   Chin, Robert K ^e   Ho, Philip Levy ^g   Tang, Chad ^a   Kurtova, Antonina V ^g   Willingham, Stephen B ^a   Pazhanisamy, Senthil K ^g   Contreras Trujillo, Humberto ^a   Storm, Theresa A ^a   Lotan, Yair ^f   Beck, Andrew H ^c   Chung, Benjamin I ^b   Alizadeh, Ash A ^b   Godoy, Guilherme ^g   Lerner, Seth P ^g   Van De Rijn, Matt ^c   Shortliffe, Linda D ^b   Weissman, Irving L ^a   Chan, Keith S ^g  

^a Stanford California and Cofounder   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Boolean analysis; Cancer stem cell; Stem and progenitor cells; Systems biology

Indexed keywords

CYTOKERATIN 14; TUMOR MARKER;

ARTICLE; BIOLOGY; BLADDER CANCER; CANCER CELL; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL SUBPOPULATION; GENE EXPRESSION; HUMAN; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRATIFICATION; UNIVARIATE ANALYSIS; XENOTRANSPLANTATION;

EID: 84857134689     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1201493109     Document Type: Erratum

References (34)

1. US Cancer Statistics Working Group (2010) United States Cancer Statistics: 1999-2007 Incidence and Mortality Web-Based Report (US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta). Available at http://apps.nccd.cdc.gov/uscs/ toptencancers.aspx. Accessed November 9, 2010.
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
3. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5:713-725.
4. Lewis SA (2000) Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 278:F867-F874.
5. Weissman I (2005) Stem cell research: Paths to cancer therapies and regenerative medicine. JAMA 294:1359-1366.
6. Dyrskjøt L, et al. (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 13:3545-3551. (Pubitemid 46955114)
7. Kim WJ, et al. (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9:3.
8. Kim WJ, et al. (2011) A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 17:478-485.
9. Lindgren D, et al. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 70:3463-3472.
10. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778-789. (Pubitemid 46622045)
11. Mitra AP, et al. (2009) Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 27:3929-3937.
12. Smith SC, et al. (2011) A 20-gene model for molecular nodal staging of bladder cancer: Development and prospective assessment. Lancet Oncol 12:137-143.
13. Monzon FA, et al. (2009) Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27:2503-2508.
14. Stransky N, et al. (2006) Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38:1386-1396. (Pubitemid 44837560)
15. Wild PJ, et al. (2005) Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11:4415-4429. (Pubitemid 40825632)
16. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H (2004) Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 10:6418-6431. (Pubitemid 39346536)
17. Karni-Schmidt O, et al. (2011) Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 178:1350-1360.
18. Sahoo D, et al. (2010) MiDReG: A method of mining developmentally regulated genes using Boolean implications. Proc Natl Acad Sci USA 107:5732-5737.
19. Chan KS, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106:14016-14021.
20. Fuchs E (1993) Epidermal differentiation and keratin gene expression. J Cell Sci Suppl 17:197-208.
21. Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403-439. (Pubitemid 34535443)
22. Johansson SL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13:291-298. (Pubitemid 27332851)
23. De La Rosette J, Smedts F, Schoots C, Hoek H, Laguna P (2002) Changing patterns of keratin expression could be associated with functional maturation of the developing human bladder. J Urol 168:709-717. (Pubitemid 34793348)
24. Sahoo D, Dill DL, Gentles AJ, Tibshirani R, Plevritis SK (2008) Boolean implication networks derived fromlarge scale,whole genomemicroarray datasets. GenomeBiol 9:R157.
25. Inlay MA, et al. (2009) Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev 23:2376-2381.
26. Stingl J, et al. (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439:993-997. (Pubitemid 43292419)
27. Lim E, et al. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907-913.
28. He X, et al. (2009) Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27:1487-1495.
29. Yang YM, Chang JW (2008) Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 26:725-733.
30. She JJ, Zhang PG, Wang ZM, Gan WM, Che XM (2008) Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biol Ther 7:1663-1668.
31. Su Y, et al. (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19:327-337.
32. Chan KS, Volkmer JP, Weissman I (2010) Cancer stem cells in bladder cancer: A revisited and evolving concept. Curr Opin Urol 20:393-397.
33. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111. (Pubitemid 33041634)
34. Chaffer CL, et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108:7950-7955.